Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST).

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Abstract Text:

Carneiro, Moutinho,Guillem Pera,Carlos Caldas,Claus Fenger,Johan Offerhaus,Vicki Save,Roger Stenling,Gabriella Nesi,U Mahlke,Hendrik ,Julio Torrado,Dimitrios H Roukos,Jean-Christophe Sabourin,Heiner Boeing,Domenico Palli,H Bas Bueno-de-Mesquita,Kim Overvad,Sheila Bingham, Clavel-Chapelon,Eiliv Lund,Antonia Trichopoulou,Jonas Manjer,Elio Riboli,Carlos A Gonzalez,

OBJECTIVE: Cardia, non-cardia and intestinal and diffuse subtypes of gastric cancer may have different trends and etiological factors. However, the available information is not always collected in population cancer registries, and heterogeneous criteria have been applied for the histopathological classification of tumors. We describe the pathological features of incident gastric and esophageal cancers identified within the European Prospective Investigation into Cancer and Nutrition (EPIC). MATERIAL AND METHODS: In an investigation on gastric and esophageal cancer (EUR-GAST) in the EPIC project, a validation study of diagnoses reported by EPIC centers was conducted by a European panel of pathologists. Original pathology reports, stained slides of tumors and the respective paraffin blocks were requested from the centers. RESULTS: The whole series encompassed 467 cancer cases (gastric and esophageal cancers). Material was available for histopathological validation in 263 cases (56%); in the remaining cases, information was retrieved from the original reports (n=110; 24%) or codes provided by the EPIC centers (n=94; 20%). Among cases submitted to histopathological validation reported originally as unknown histotype or unknown site, a specific diagnosis was made in 95% and 74% of the cases, respectively. In cases for which only the original reports were available, the respective percentages were 46% and 67%. Gastric adenocarcinomas were classified according to site (cardia (29.4%), non-cardia (48.2%) and unknown (22.4%)) and histological type (intestinal (33.4%), diffuse (33.7%) and mixed, unclassified or unknown (32.9%)). Frequency of cardia was higher in Northern countries (35%) than in Mediterranean countries (18%). CONCLUSIONS: In addition to providing epidemiological data within the EPIC cohort on gastric and esophageal adenocarcinomas, the results reported here confirm the relevance of a validation study, notably for multicenter studies.

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Publishing Authors By Initials

F Carneiro,C Moutinho,G Pera,C Caldas,C Fenger,J Offerhaus,V Save,R Stenling,G Nesi,U Mahlke,H ,J Torrado,DH Roukos,JC Sabourin,H Boeing,D Palli,HB Bueno-de-Mesquita,K Overvad,S Bingham,F Clavel-Chapelon,E Lund,A Trichopoulou,J Manjer,E Riboli,CA Gonzalez,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Scandinavian journal of gastroenterology

VOLUME: 42

Page Numbers: 618-27

Journal Abbreviation:

ISSN: 0036-5521

DAY: 24

MONTH: May

YEAR: 2007

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 60105

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST).

AFFILIATION: Institute of Molecular Pathology and Immunology of the University of Porto, Portugal, and Hutchison/MRC Research Centre, Addenbrooke's Hospital, Cambridge, UK. fcarneiro@ipatimup.pt

Country: Norway

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Scand J Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pathology findings and validation of gastric and esophageal cancer cases in a European cohort EPIC/EUR-GAST Related Publications

• A Family-Based Intervention Strategy for Addressing Childhood Obesity in an At-Risk Population: 1354: Board #117 May 30 9:30 AM - 11:00 AM.
• Adaptive model of the gradient index of the human lens. I. Formulation and model of aging ex vivo lenses.
• Beach morphodynamics forcements in oiled shorelines: Coupled physical and chemical processes during and after fuel burial.
• Biological research on drug abuse and addiction in Hispanics: current status and future directions.
• Citrate metabolism by Enterococcus faecium and Enterococcus durans isolated from goat's and ewe's milk: influence of glucose and lactose.
• Disease evolution of patients with mycosis fungoides--a report of 30 cases.
• Evaluation of the quality of the water in El Hondo natural park located in the east of Spain.
• Evolution of the amygdaloid complex in vertebrates, with special reference to the anamnio-amniotic transition.
• Genetic characterization of 2,4,6-trichlorophenol degradation in Cupriavidus necator JMP134.
• Human infection by Angiostrongylus costaricensis in Venezuela: first report of a confirmed case.
• Identification of ethanol responsive domains of adenylyl cyclase.
• Inbreeding and Reproduction in Endangered Ungulates: Preservation of Genetic Variation through the Organization of Genetic Resource Banks.
• Involvement of specific laminins and nidogens in the active remodeling of the basal lamina of labial salivary glands from patients with Sjögren's syndrome.
• Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation.
• Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
• New trends in first-line treatment of non-small cell lung cancer: combinations without platinum.
• Noninvasive evaluation of allergic and irritant contact dermatitis by in vivo reflectance confocal microscopy.
• P2Y2 receptors induced cell surface redistribution of alpha(v) integrin is required for activation of ERK 1/2 in U937 cells.
• Parathyroid hormone assay: problems and opportunities.
• Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST).
• Pharmacological study of uzarigenin-glucoside-canaroside.
• Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.
• Polymorphism in the 3' UTR of the IL12B gene is associated with Chagas' disease cardiomyopathy.
• Rehabilitation and recovery in schizophrenia.
• Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.
• Src and Pyk2 mediate angiotensin II effects in cultured rat astrocytes.
• The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A.
• [Caffeine inhibits chemoreceptor responses to hypoxia.]
• [Effects of the implementation of Universal Access with Explicit Guaranties (AUGE) Plan on the quality of care of patients with terminal renal failure]
• [Moonlighting physicians: analysis of its causes and consequences.]